Annual Accounts Payable
$31.72 M
+$8.68 M+37.66%
31 December 2023
Summary:
Esperion Therapeutics annual accounts payable is currently $31.72 million, with the most recent change of +$8.68 million (+37.66%) on 31 December 2023. During the last 3 years, it has fallen by -$20.26 million (-38.97%). ESPR annual accounts payable is now -38.97% below its all-time high of $51.98 million, reached on 31 December 2020.ESPR Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$34.86 M
-$12.80 M-26.86%
30 September 2024
Summary:
Esperion Therapeutics quarterly accounts payable is currently $34.86 million, with the most recent change of -$12.80 million (-26.86%) on 30 September 2024. Over the past year, it has increased by +$8.65 million (+33.00%). ESPR quarterly accounts payable is now -32.92% below its all-time high of $51.98 million, reached on 31 December 2020.ESPR Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ESPR Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +37.7% | +33.0% |
| 3 y3 years | -39.0% | +68.1% |
| 5 y5 years | -29.4% | +46.9% |
ESPR Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -39.0% | +80.6% | -26.9% | +171.7% |
| 5 y | 5 years | -39.0% | +80.6% | -32.9% | +171.7% |
| alltime | all time | -39.0% | +6559.3% | -32.9% | +7219.8% |
Esperion Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $34.86 M(-26.9%) |
| June 2024 | - | $47.67 M(+67.7%) |
| Mar 2024 | - | $28.43 M(-10.4%) |
| Dec 2023 | $31.72 M(+37.7%) | $31.72 M(+21.0%) |
| Sept 2023 | - | $26.21 M(+6.7%) |
| June 2023 | - | $24.56 M(+43.9%) |
| Mar 2023 | - | $17.07 M(-25.9%) |
| Dec 2022 | $23.04 M(+31.2%) | $23.04 M(+24.0%) |
| Sept 2022 | - | $18.58 M(+44.8%) |
| June 2022 | - | $12.83 M(-52.2%) |
| Mar 2022 | - | $26.83 M(+52.8%) |
| Dec 2021 | $17.56 M(-66.2%) | $17.56 M(-15.4%) |
| Sept 2021 | - | $20.75 M(-29.3%) |
| June 2021 | - | $29.35 M(-3.3%) |
| Mar 2021 | - | $30.34 M(-41.6%) |
| Dec 2020 | $51.98 M(+80.1%) | $51.98 M(+195.6%) |
| Sept 2020 | - | $17.58 M(-40.8%) |
| June 2020 | - | $29.69 M(+96.4%) |
| Mar 2020 | - | $15.11 M(-47.6%) |
| Dec 2019 | $28.86 M(-35.7%) | $28.86 M(+21.6%) |
| Sept 2019 | - | $23.73 M(-16.4%) |
| June 2019 | - | $28.40 M(-14.6%) |
| Mar 2019 | - | $33.27 M(-25.9%) |
| Dec 2018 | $44.89 M | $44.89 M(+141.0%) |
| Sept 2018 | - | $18.63 M(-17.1%) |
| June 2018 | - | $22.48 M(+87.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2018 | - | $11.96 M(-41.3%) |
| Dec 2017 | $20.38 M(+343.4%) | $20.38 M(+4.5%) |
| Sept 2017 | - | $19.50 M(+4.2%) |
| June 2017 | - | $18.71 M(+60.8%) |
| Mar 2017 | - | $11.64 M(+153.2%) |
| Dec 2016 | $4.59 M(+549.9%) | $4.59 M(+157.7%) |
| Sept 2016 | - | $1.78 M(+13.9%) |
| June 2016 | - | $1.57 M(+1.7%) |
| Mar 2016 | - | $1.54 M(+117.8%) |
| Dec 2015 | $707.00 K(-65.3%) | $707.00 K(-64.3%) |
| Sept 2015 | - | $1.98 M(-40.1%) |
| June 2015 | - | $3.31 M(+14.0%) |
| Mar 2015 | - | $2.90 M(+42.1%) |
| Dec 2014 | $2.04 M(-8.6%) | $2.04 M(-38.2%) |
| Sept 2014 | - | $3.30 M(-21.7%) |
| June 2014 | - | $4.21 M(+100.7%) |
| Mar 2014 | - | $2.10 M(-6.0%) |
| Dec 2013 | $2.23 M(+368.6%) | $2.23 M(+14.8%) |
| Sept 2013 | - | $1.94 M(+17.4%) |
| June 2013 | - | $1.66 M(+78.7%) |
| Mar 2013 | - | $926.80 K(+94.6%) |
| Dec 2012 | $476.30 K(-31.1%) | $476.30 K |
| Dec 2011 | $691.20 K(-59.0%) | - |
| Dec 2002 | $1.69 M(-42.3%) | - |
| Dec 2001 | $2.92 M(-25.7%) | - |
| Dec 2000 | $3.94 M(+176.2%) | - |
| Dec 1999 | $1.43 M | - |
FAQ
- What is Esperion Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Esperion Therapeutics?
- What is Esperion Therapeutics annual accounts payable year-on-year change?
- What is Esperion Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Esperion Therapeutics?
- What is Esperion Therapeutics quarterly accounts payable year-on-year change?
What is Esperion Therapeutics annual accounts payable?
The current annual accounts payable of ESPR is $31.72 M
What is the all time high annual accounts payable for Esperion Therapeutics?
Esperion Therapeutics all-time high annual accounts payable is $51.98 M
What is Esperion Therapeutics annual accounts payable year-on-year change?
Over the past year, ESPR annual accounts payable has changed by +$8.68 M (+37.66%)
What is Esperion Therapeutics quarterly accounts payable?
The current quarterly accounts payable of ESPR is $34.86 M
What is the all time high quarterly accounts payable for Esperion Therapeutics?
Esperion Therapeutics all-time high quarterly accounts payable is $51.98 M
What is Esperion Therapeutics quarterly accounts payable year-on-year change?
Over the past year, ESPR quarterly accounts payable has changed by +$8.65 M (+33.00%)